Last mentioned: Mar 25, 2026
Options Surge
Traders purchase large volume of call options following clinical data reports.
Clinical Data Release
Early data for RNA therapies in FSHD and DM1 shows promise.
Clinical Data Release
Early data for FSHD and DM1 therapies reported by STAT and Endpoints News.
Options Surge
Traders purchase large volumes of call options following the clinical updates.
Regulatory Strategy
Sarepta announces plan to seek full FDA approval for exon-skipping drugs.
Analyst Revisions
Multiple brokerages raise price targets for SRPT stock.
Price Target Update
Brokerages adjust targets, including a raise to $9.00 by some analysts.
SEC Filing
Company files 8-K regarding changes in director and officer elections.
Financial Results
Sarepta files results of operations and financial condition with the SEC.
Traders have flooded Sarepta Therapeutics with call options following positive early-stage data for its RNA-based rare disease therapies. This surge in bullish sentiment suggests high market confidence in the company's clinical pipeline expansion beyond its core Duchenne muscular dystrophy franchise.
Bullish options activity for Sarepta Therapeutics (SRPT) spiked on March 25, 2026, as the market reacted to promising early data for its RNA-based rare disease pipeline. The increased trading volume coincides with the company’s strategic push for full FDA approval of its core Duchenne muscular dystrophy portfolio.